Table 4 Analysis of multiple features of 184 Chinese Sjögren’s syndrome patients with neurological involvement
From: Clinical features and risk factors of neurological involvement in Sjögren’s syndrome
pSS | sSS | P value | |
|---|---|---|---|
125 | 59 | ||
Age (years) | 52.81 ± 14.95 | 47.93 ± 16.22 | 0.084 |
Sex, female, n (%) | 109 (87.20%) | 56 (94.90%) | 0.126 |
Disease duration (months) | 51.57 ± 66.84 | 46.07 ± 68.73 | 0.955 |
Xerostomia, n (%) | 88 (70.40%) | 50 (84.70%) | 0.036 |
Xerophthalmia, n (%) | 44 (35.20%) | 22 (37.30%) | 0.783 |
ESSDAI | 7.84 ± 2.83 | 8.81 ± 3.45 | 0.129 |
ESSPRI | 2.77 ± 1.34 | 3.38 ± 1.63 | 0.038 |
Liver dysfunction, n (%) | 41 (33.60%) | 28 (49.10%) | 0.047 |
Articular involvement, n (%) | 46 (36.80%) | 40 (67.80%) | < 0.001 |
LSGB, lymphocytic focus ≥ 1 | 76 (60.80%) | 50 (84.70%) | 0.001 |
Saliva gland atrophy | 78 (70.30%) | 46 (86.80%) | 0.021 |
Albumin levels (g/L) | 37.35 ± 5.73 | 34.12 ± 5.94 | < 0.001 |
Low C3 level (< 0.9 g/L) | 54 (46.20%) | 36 (65.50%) | 0.018 |
Low C4 level (< 0.1 g/L) | 6 (5.30%) | 11 (20.80%) | 0.005 |
Antiphospholipid syndrome | 0 | 6(10.17%) | < 0.001 |